Dec 4, 2012 by Brenton Flynn and Max Macaluso1 Pharmaceutical Company's Accelerated DividendDozens of companies are either paying special dividends or accelerating their regularly scheduled dividends to get ahead of the fiscal cliff. Here's one in the pharmaceutical industry.
Dec 3, 2012 by Brenton Flynn and Max MacalusoHuge Health Care Fraud AllegationsThe recent 60 Minutes piece on Health Management Associates has the company scrambling to explain itself.
Dec 1, 2012 by Brenton Flynn and Max MacalusoSEC Sleuth: Abbott Labs, Questcor, Dendreon, Express Scripts, and MAKO SurgicalMotley Fool analyst Brenton Flynn pours through some recent SEC filings to uncover some interesting info-nuggets.
Nov 30, 2012 by Brenton Flynn and Dave WilliamsonToday's Biotech BreakupBioCryst and Presidio Pharmaceuticals call it quits.
Nov 30, 2012 by Brenton FlynnWill the Fiscal Cliff Crush MAKO's Q4?A look at the fiscal cliff in the health care sector.
Nov 30, 2012 by Brenton Flynn and Dave WilliamsonDeja Vu for QuestcorAn announcement from Aetna yesterday has Questcor shares down 7%.
Nov 29, 2012 by Brenton Flynn and Max MacalusoIt's Official -- Abbott Labs Will Change ForeverThe details are in: here's everything every Abbott Labs investor needs to know about the upcoming spinoff.
Nov 28, 2012 by Brenton Flynn and Max MacalusoMAKO Surgical Conference ScuttlebuttMAKO Surgical clears up some investor concerns about the timing of its recent second offering.
Nov 28, 2012 by Brenton Flynn and Max Macaluso1 Business Reeling From the Fiscal CliffA look at the fiscal cliff in the health care sector.
Nov 28, 2012 by Brenton FlynnWill the Fiscal Cliff Hurt Intuitive Surgical?A look at the fiscal cliff in the health care sector.
Nov 27, 2012 by Brenton Flynn and Max MacalusoAcadia Skyrockets After Phase 3 SuccessACADIA's phase 3 trial results have share prices up staggeringly.
Nov 27, 2012 by Brenton Flynn1 More Milestone for This Blockbuster DrugThe potential for Abbott Labs' flagship drug continues to snowball.
Nov 27, 2012 by Brenton Flynn and Max MacalusoWhy Peregrine Popped TodayAfter a major September tumble, Peregrine jumped 26% today.
Nov 27, 2012 by Brenton Flynn and Max MacalusoThis Oil Maker Gets KrilledNeptune shares fall sharply on its first day trading since a plant explosion.
Nov 27, 2012 by Brenton FlynnAnother Emerging Markets Move for Big PharmaGlaxoSmithKline is one pharmaceutical company taking advantage of massive emerging market growth opportunities.
Nov 27, 2012 by Brenton FlynnSpectrum, Questcor, and Overhanging RisksSpectrum's top selling drug could be a dud.
Nov 27, 2012 by Brenton FlynnThis Soaring Biotech Is Ready to Go Even HigherRegeneron is already profitable and making a mint, but this new approval means it has much further to go.
Nov 27, 2012 by Brenton Flynn2 Must-Watch Medical Technology Trends2 things every medical technology investor should have their eye on right now.
Nov 21, 2012 by Brenton FlynnSome Big Changes From This Benefit ManagerA close look at Express Scripts' latest SEC filing.
Nov 21, 2012 by Brenton Flynn and Max MacalusoWhat's Changed With Express Scripts?A close look at some economic climate pessimism from Express Scripts.
